Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos.
Landos Biopharma shares jumped 171.2% to $21.70 on Monday.
Here are some other stocks moving in today's mid-day session.
Gainers
Next.e.GO N.V. (NASDAQ: EGOX) shares jumped 85.8% to $0.0730 after falling around 22% on Friday.
Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.
MicroAlgo Inc. (NASDAQ: MLGO) climbed 34.3% to $5.40 after declining around 5% on Friday.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) gained 32.4% to $3.4690. XTL Biopharmaceuticals recently entered into a binding term sheet to acquire all of the issued and outstanding share capital of Social Proxy.
Nkarta, Inc. (NASDAQ: NKTX) gained 23.3% to $11.00 after the company priced $240 million underwritten offering.
Target Hospitality Corp. (NASDAQ: TH) jumped 21.3% to $10.82 after the company received a buyout offer from TDR Capital.
Swvl Holdings Corp. (NASDAQ: SWVL) rose 21.2% to $11.26.
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) surged 21% to $0.6949.
Lucid Group, Inc. (NASDAQ: LCID) jumped 18.7% to $3.29 after the company announced a $1 billion investment by an affiliate of PIF.
Sagimet Biosciences Inc. (NASDAQ: SGMT) rose 16.9% to $5.27 after the company reported FY results and announced the appointment of Tim Walbert and Paul Hoelscher to its Board of Director.
Ocugen, Inc. (NASDAQ: OCGN) jumped 16.4% to $1.9101. The Third Circuit Court of Appeals recently upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen.
Flora Growth Corp. (NASDAQ: FLGC) shares gained 15.2% to $1.8206 after surging around 34% on Friday.
Forge Global Holdings, Inc. (NYSE: FRGE) shares gained 14.5% to $2.67 after ...
Benzinga
